Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.

Marchesi, Francesco; Salmanton-García, Jon; Buquicchio, Caterina; Itri, Federico; Besson, Caroline; Dávila-Valls, Julio; Martín-Pérez, Sonia; Fianchi, Luana; Rahimli, Laman; Tarantini, Giuseppe; Grifoni, Federica Irene; Sciume, Mariarita; Labrador, Jorge; Cordoba, Raul; López-García, Alberto; Fracchiolla, Nicola S; Farina, Francesca; Ammatuna, Emanuele; Cingolani, Antonella; García-Bordallo, Daniel; Gräfe, Stefanie K; Bilgin, Yavuz M; Dargenio, Michelina; González-López, Tomás José; Guidetti, Anna; Lahmer, Tobias; Lavilla-Rubira, Esperanza; Méndez, Gustavo-Adolfo; Prezioso, Lucia; Schönlein, Martin; Van Doesum, Jaap; Wolf, Dominik; Hersby, Ditte Stampe; Magyari, Ferenc; Van Praet, Jens; Petzer, Verena; Tascini, Carlo; Falces-Romero, Iker; Glenthøj, Andreas; Cornely, Oliver A; Pagano, Livio     «

Marchesi, Francesco; Salmanton-García, Jon; Buquicchio, Caterina; Itri, Federico; Besson, Caroline; Dávila-Valls, Julio; Martín-Pérez, Sonia; Fianchi, Luana; Rahimli, Laman; Tarantini, Giuseppe; Grifoni, Federica Irene; Sciume, Mariarita; Labrador, Jorge; Cordoba, Raul; López-García, Alberto; Fracchiolla, Nicola S; Farina, Francesca; Ammatuna, Emanuele; Cingolani, Antonella; García-Bordallo, Daniel; Gräfe, Stefanie K; Bilgin, Yavuz M; Dargenio, Michelina; González-López, Tomás José; Guidetti, An...     »

Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.      «

Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM....     »